Enveric Biosciences (ENVB)
NASDAQ:ENVB
Want to see ENVB full AI Analyst Report?
ENVB Stock Chart & Stats
$3.72
-$0.12(-23.95%)
At close: 4:00 PM EST
$3.72
-$0.12(-23.95%)
Day’s Range― - ―
52-Week Range$1.71 - $17.83
Previous CloseN/A
Volume362.16K
Average Volume (3M)781.31K
Market Cap
$6.77M
Enterprise Value-$2.64M
Total Cash (Recent Filing)$4.68M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.71
Next Earnings
May 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-14610.70
Shares Outstanding1,985,535
10 Day Avg. Volume899,153
30 Day Avg. Volume781,309
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.29
Price to Sales (P/S)0.00
P/FCF Ratio-0.15
Enterprise Value/Market Cap-0.39
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit13.15
Enterprise Value/Ebitda0.31
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-315
Revenue Forecast (FY)$10.00M
Bulls Say, Bears Say
Bulls Say
Clinical-stage, Differentiated PipelineEnveric’s focus on neuroplastogenic small-molecule therapeutics and clinical-stage programs gives it a differentiated scientific position in neuropsychiatric disorders. A clear R&D niche supports long-term product read-through and partnerships as clinical data matures over months to years.
Very Low LeverageMinimal debt reduces refinancing and interest-rate risk for a pre-revenue biotech. Low leverage preserves strategic optionality, enabling the company to prioritize R&D spending and licensing discussions without near-term covenant pressure or large fixed interest obligations.
Access To Equity Capital (ATM Expansion)Expanding ATM capacity is a structural funding tool that materially increases flexibility to support trials and operations. For a cash-burning clinical-stage company, ready access to incremental equity issuance helps sustain program timelines and reduces risk of abrupt funding shortfalls.
Bears Say
No Revenue BaseAbsence of revenues leaves the business dependent on external financing and grants no operating cushion to absorb R&D spend. Over the medium term this raises commercialization risk and lengthens the timeline before the company can self-fund programs or demonstrate sustainable margins.
Ongoing Cash BurnConsistent negative operating and free cash flows indicate the company is consuming capital to fund development. Continued cash burn requires repeated financing, which can interrupt R&D cadence if markets tighten and constrains strategic choices for partner negotiations or program expansion.
Reliance On Equity Issuance And Governance ActionsSeeking broad authority to reverse split and greatly expand authorized shares is a structural sign of reliance on equity markets to fund operations. This increases dilution risk, may complicate shareholder alignment, and signals potential future capital raises are likely to fund ongoing development.
Enveric Biosciences News
ENVB FAQ
What was Enveric Biosciences’s price range in the past 12 months?
Enveric Biosciences lowest stock price was $1.71 and its highest was $17.83 in the past 12 months.
What is Enveric Biosciences’s market cap?
Enveric Biosciences’s market cap is $6.77M.
When is Enveric Biosciences’s upcoming earnings report date?
Enveric Biosciences’s upcoming earnings report date is May 19, 2026 which is in 14 days.
How were Enveric Biosciences’s earnings last quarter?
Enveric Biosciences released its earnings results on Mar 27, 2026. The company reported $0.85 earnings per share for the quarter, beating the consensus estimate of N/A by $0.85.
Is Enveric Biosciences overvalued?
According to Wall Street analysts Enveric Biosciences’s price is currently Overvalued.
Does Enveric Biosciences pay dividends?
Enveric Biosciences does not currently pay dividends.
What is Enveric Biosciences’s EPS estimate?
Enveric Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Enveric Biosciences have?
Enveric Biosciences has 1,985,535 shares outstanding.
What happened to Enveric Biosciences’s price movement after its last earnings report?
Enveric Biosciences reported an EPS of $0.85 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -4.787%.
Which hedge fund is a major shareholder of Enveric Biosciences?
Currently, no hedge funds are holding shares in ENVB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Enveric Biosciences
Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida.
Technical Analysis
Biodexa Pharmaceuticals
―
―
Indaptus Therapeutics
―
GT Biopharma
―
Artelo Biosciences
―
Ownership Overview
9.58% Insiders
0.42% Mutual Funds
0.85% Other Institutional Investors
87.59% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---